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Introduction
The safety of antiepileptic drug (AED) use in pregnancy
has been an unsolved puzzle for generations. Given the
fact that women with epilepsy compromise only around
1% of the population, tend to have a decreased fertility
rate, and are generally socially and economically disad-
vantaged, conclusions derived from individual clinical
researches are generally limited by their statistic power
due to the small sample size. To solve this problem, preg-
nancy registries for women with epilepsy were founded
to pool individual data series together to gain a whole
view of the issue [1–4].
The Taiwanese Registry of Epilepsy and Pregnancy
(TREP) was officially launched in 2004 by Dr Chi-Wan
Lai with the cooperation of the Taiwan Epilepsy Society
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SUMMARY
Objective: To present the descriptive statistics of the Taiwanese Registry of Epilepsy and Pregnancy (TREP) for the
first 2 years.
Materials and Methods: The pregnancies were recruited from May 2004 to January 2006 with a data format
compatible with the International Registry of Antiepileptic Drugs and Pregnancy (EURAP) by referral. The data
were collected from either face-to-face interview, telephone interview, or chart review by a research nurse. Five
questionnaires (A–E) were required for each pregnancy. The preliminary data for the first 2 years are presented
with general descriptive statistics.
Results: Until January 2006, 43 pregnancies have been registered. Questionnaire A was completed in 43 cases,
questionnaire B completed in 40 cases, questionnaire C completed in 34 cases, questionnaire D completed in
27 cases, and questionnaire E in eight cases. Among the 39 pregnancies known to take antiepileptic drugs (AEDs)
during pregnancy, 28 pregnancies took one AED, nine pregnancies took two AEDs, and two pregnancies took
three AEDs. The most commonly used drug was carbamazepine (19/39, 48.72%). Among the 27 pregnancies,
who had delivered, the cesarean section rate was 44.44% (12/27), the premature birth rate was 7.41% (2/27),
and the fetal malformation rate was 3.7% (1/27).
Conclusion: The preliminary data concluded the efforts of TREP for the first 2 years. Although it is still premature to
project a trend out of current data, the registry is expected to provide critical information to local prenatal counsel-
ing and contribute further to the international EURAP database. [Taiwanese J Obstet Gynecol 2007;46(1):47–49]
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and the Taiwan Society of Perinatology and joined 
the International Registry of Antiepileptic Drugs and
Pregnancy (EURAP), an international AEDs and preg-
nancy registry originated in Europe, in the same year.
The data center and relevant services are maintained
and staffed at the Pregnancy Assessment Center in the
Mackay Memorial Hospital, Taipei, Taiwan. The descrip-
tive statistics of the first 2 years and relevant discussion
are presented in this article.
Materials and Methods
The patients were recruited from May 2004 to January
2006 and the data were stored in a central database 
of the TREP managed by the Taiwan Epilepsy Society
and the Taiwan Society of Perinatology. The data for-
mat was based on the five questionnaires (A–E) of the
EURAP and was also customized for our local needs.
Questionnaire A was to be completed as early as possi-
ble if pregnancy was confirmed. Questionnaire B was to
be completed at 14–24 weeks, questionnaire C at 24–28
weeks, questionnaire D at birth, and questionnaire E at
1 year of age. A telephone help line was offered to the
general public for general enquiry, health education,
and data collection. Women with epilepsy who became
pregnant were eligible to register. The data were col-
lected by a research nurse in the Pregnancy Assessment
Center of the Mackay Memorial Hospital, Taipei, Taiwan
with either face-to-face interview, telephone interview, or
chart review. The patients were referred by their doctors
or they might also be self-referred with the telephone help
line. All patients were asked to sign a consent form and
the patients meeting the data collection criteria of EURAP
were pooled to the EURAP database with the provided
software from the EURAP. The patients in the TREP data-
base were reviewed with general descriptive statistics.
Results
Until January 2006, there were 43 singleton pregnancies,
totally 41 women, registered in the central database.
There were no multiple pregnancies in our series. Among
the registered pregnancies, 14 were entered in 2004 and
29 in 2005. Questionnaire A was completed in 43
pregnancies, questionnaire B completed in 40 preg-
nancies, questionnaire C completed in 34 pregnancies,
questionnaire D completed in 27 pregnancies, and ques-
tionnaire E completed in eight pregnancies. Among the
43 pregnancies, 36 (36/43, 83.72%) pregnancies were
referred by their doctors, and seven (7/43, 16.28%)
pregnancies were self-referred.
The use of AED was not specified in three pregnan-
cies (3/43, 6.98%) and the use of AED has been
stopped before pregnancy in one pregnancy (1/43,
2.33%). Among the 39 pregnancies with the use of AED
specified in the database, there were 28 pregnancies tak-
ing one AED (28/39, 71.79%), nine pregnancies taking
two AEDs (9/39, 23.08%), and two pregnancies taking
three AEDs (2/39, 5.13%).
The most commonly used drugs were carbama-
zepine (19/39, 48.72%), phenytoin (8/39, 20.51%),
lamotrigine (7/39, 17.95%), valproate sodium (7/39,
17.95%), topiramate (5/39, 12.82%), and phenobar-
bital (3/39, 7.69%).
Among the 27 pregnancies which had delivered,
there were 12 cesarean sections (12/27, 44.44%) and
15 vaginal deliveries (15/27, 55.56%). The premature
birth rate was 7.41% (2/27), with one at 34 and the
other at 35 completed weeks. Fetal distress leading to
cesarean section was reported in three pregnancies
(3/27, 11.11%) and there was one breech (1/27, 3.7%).
One woman had an epilepsy attack in the postoperative
room after the cesarean section (1/27, 3.7%). No other
significant pregnancy complications were reported. In
addition, fetal malformations were found in one infant
after birth (1/27, 3.70%) in one pregnancy taking pheny-
toin and valproic acid. The infant was small for the ges-
tational age and the malformations included preaxial
polydactyly in the left hand, low-positioned thumb in
the right hand, postaxial polysyndactyly in the right foot,
rocker-bottom feet, arachnodactyly, craniosynostosis
of the metopic and coronal sutures, microcephaly, and
trigonocephaly.
Among the 43 registered singleton pregnancies, there
were 35 primigravida (35/43, 81.40%) and there were
11 children delivered in the previous pregnancies. No
malformation was reported in the 11 children by the
women. There were three pregnancies resulting in
intrauterine fetal death at 12 weeks in the database.
Among them, two pregnancies were of the same women
taking carbamezepine; however, the use of AED was
not specified in the other pregnancy.
The average maternal age on the expected date of
delivery was 28.50 years, and the standard deviation
was 3.87 years. Among the delivered term pregnancies,
the average birth weight was 2,925.07 g, and the stan-
dard deviation was 439 g.
Discussion
Teratogenicity is a major concern of the pregnant
women with epilepsy who choose to reproduce. In addi-
tion, it is generally believed that pregnant women with
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epilepsy tend to have a higher incidence of pregnancy
complications; however, Richmond et al reported that
although the rates of nonproteinuric hypertension,
induction of labor, and fetal cardiovascular malforma-
tions were increased in pregnant women with epilepsy,
the rates of other antenatal, intrapartum, and neonatal
complications and congenital malformations were simi-
lar to the women without epilepsy [5]. Richmond et al
also concluded that as long as appropriate care is taken
to the pregnant women with epilepsy, they are not at an
increased risk of having obstetric complications. Endo
et al also reported that for pregnant women with and
without epilepsy, no significant difference was found
in complications during pregnancy, types of delivery,
or complications at delivery, excluding the frequency
of abnormal rotation in the birth canal [6]. Although
our result is still preliminary, the rates of major malfor-
mation and pregnancy complications seem to be not
increased.
There was one case of malformation in our 27 deliv-
ered singleton pregnancies. The woman took phenytoin
and valproate sodium before pregnancy and through
pregnancy, exposing her to the risks of fetal hydantoin
syndrome and fetal valproate syndrome [7]. She was
prescribed to take folic acid in pregnancy; however,
she was low in socioeconomic status and was not quite
compliant with the prenatal care. As the use of valproate
during pregnancy is associated with an increased risk
of major congenital malformations and developmental
delay [8], it was suggested that pregnancies in women
taking valproate should be planned to minimize the
risk of malformation [9]. In contrast, the use of pheny-
toin in pregnancy is not associated with an increased risk
of malformation, either in monotherapy or in polyther-
apy without valproate. However, the postnatal findings
suggest that both phenytoin and valproate might have
contributed to the phenotype of the newborn.
It was reported that carbamazepine as monotherapy
was associated with the lowest risk of major congenital
malformation [10]. Among the 39 pregnancies with
the use of AED specified in our series, 13 pregnancies
(13/39, 33.33%) used carbamazepine as monotherapy.
Olafsson et al reported a twofold increase of the
cesarean section rate in pregnant women with epilepsy
in Iceland given the fact that the incidence of adverse
events during pregnancy for pregnant women with
epilepsy was not different from the general population
[11]. Our series also shows a high cesarean section
rate at 44.44%, and this suggests the decision to have
a cesarean section might not be limited to obstetric
indications and this warrants further analysis in the
future.
In conclusion, our article presents the preliminary
descriptive statistics of the TREP, and it portrays 
a general level of care and serves as an auditing tool of
clinical practice for pregnant women with epilepsy in
Taiwan. The registry will be carried on as a joint project
of the Taiwan Epilepsy Society and the Taiwan Society of
Perinatology.
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